Vebreltinib

Vebreltinib (also known as bozitinib) is a pharmaceutical drug used for the treatment of cancer.

Vebreltinib selectively binds to c-Met, preventing its phosphorylation and thereby disrupting c-Met signal transduction pathways.

In China, it is approved for the treatment of non-small-cell lung cancer (NSCLC) with MET exon 14 skipping mutations.